Stock ONCY ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Oncolytics Biotech Inc. Nasdaq

Equities

ONCY

CA6823108759

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-07-02 EDT 		5-day change 1st Jan Change
0.99 USD -0.52% Intraday chart for Oncolytics Biotech Inc. -1.98% -26.67%
06-27 Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program MT
06-27 Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors
Oncolytics Biotech Provides Outlook for 2024
Oncolytics Says Anal Cancer Cohort Of GOBLET Phase 1/2 Study Meets "Criteria For Efficacy"; Provides Update on Pancreatic Cancer Program
Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
Oncolytics Biotech Inc. Provides Update on Pancreatic Cancer Program for Pelareorep
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. ONCY Stock
  5. News Oncolytics Biotech Inc.
  6. Other languages